Related references
Note: Only part of the references are listed.Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study
Rajen Mody et al.
BLOOD (2008)
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets.: Report of the BIOMED-2 Concerted Action BHM4-CT98-3936
P. A. S. Evans et al.
LEUKEMIA (2007)
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Peter Dreger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
Marco Ladetto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
C Pott et al.
BLOOD (2006)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma:: outcome related to remission pretransplant
NS Andersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
AM Gianni et al.
BLOOD (2003)
Outcome of autologous transplantation for mantle cell lymphoma:: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant registries
E Vandenberghe et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma
NS Andersen et al.
EXPERIMENTAL HEMATOLOGY (2002)
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma:: a prospective study
F Lefrère et al.
LEUKEMIA (2002)
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma
J Mangel et al.
SEMINARS IN ONCOLOGY (2002)
A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors
NS Andersen et al.
EUROPEAN JOURNAL OF CANCER (2002)